<div id="readability-page-1"><p>Bank of America Securities analyst Jason Zemansky reiterated a Buy rating on Rocket Pharmaceuticals today and set a price target of $8.00.</p><h3>Meet Your ETF AI Analyst</h3><ul><li> Discover how TipRanks' <i>ETF</i> AI Analyst  can help you make smarter investment decisions </li><li>   Explore ETFs TipRanks' users love  and see what insights the <b><i>ETF</i> AI Analyst</b> reveals about the ones you follow.</li></ul> <p>Zemansky covers the Healthcare sector, focusing on stocks such as Cytokinetics, Kura Oncology, and Arcus Biosciences. According to TipRanks, Zemansky has an average return of <span>21.3%</span> and a 60.64% success rate on recommended stocks. </p> <p>In addition to Bank of America Securities, Rocket Pharmaceuticals also received a Buy from Wedbush’s Yun Zhong in a report issued on November 7. However, on the same day, Needham maintained a Hold rating on Rocket Pharmaceuticals (NASDAQ: RCKT).</p></div>

RCKT

<p>Bank of America Securities analyst Jason Zemansky reiterated a Buy rating on Rocket Pharmaceuticals with a price target of $8.00. Zemansky has an average return of 21.3% and a 60.64% success rate. Wedbush’s Yun Zhong also rated Rocket Pharmaceuticals a Buy, while Needham maintained a Hold rating.</p>

Rocket Pharmaceuticals (RCKT) Receives a Buy from Bank of America Securities